MSB 3.19% 97.0¢ mesoblast limited

"U.S. FDA supports an accelerated approval pathway for...

  1. 16,635 Posts.
    lightbulb Created with Sketch. 2374
    "U.S. FDA supports an accelerated approval pathway for Rexlemestrocel-L, Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product"

    Nope, that was the misleading headline of the announcement from Mesoblast.

    The actual detail DIDN'T say that. It said the data MAY support an accelerated approval pathway. In my view, thats quite a different from what the company suggested in the headline they released. But it's had the intended effect of a temporary share price appreciation to get a bit more money in the company's account while giving the short traders a free gift.
    Last edited by whytee: 18/03/24
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.0¢
Change
0.030(3.19%)
Mkt cap ! $1.107B
Open High Low Value Volume
94.0¢ 98.0¢ 92.0¢ $3.342M 3.477M

Buyers (Bids)

No. Vol. Price($)
4 33313 97.0¢
 

Sellers (Offers)

Price($) Vol. No.
97.5¢ 73982 2
View Market Depth
Last trade - 16.10pm 03/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.